Can a single, cheap pill combat cardiovascular disease?
- Details
- Category: Research
Volunteers are being recruited in Ireland, the Netherlands and the UK to participate in a two-year trial of a single 'polypill' designed to prevent heart attack and stroke. The trials are financed in part by the UMPIRE (Use of a multidrug pill in reducing cardiovascular events) project, which has received EUR 3 million under the Health Theme of the Seventh Framework Programme (FP7).
How Unbranded Websites Can Extend Brand Reach throughout the Patient Life Cycle?
- Details
- Category: Research
Consumer reliance on condition-focused content during the disease research process, growing emphasis on customer care throughout the treatment continuum, and uncertainty around the DTC regulatory environment is prompting increased interest in unbranded online initiatives.
The IT @ Networking Awards 2010
- Details
- Category: Research
The goal of the IT @ Networking Awards 2010 (IT @ 2010), is to honour and promote outstanding healthcare IT solutions. The core aim of IT @ 2010 is to learn from the achievements of the very best IT installations on the globe.
Study Reveals Exciting Physician Growth in the Areas of Mobile, Social, and Online Access
- Details
- Category: Research
Physicians show continued adoption of mobile and social media for professional purposes, as well as increasing dependency on digital resources at the point of care, according to pharmaceutical and healthcare market research company Manhattan Research's latest Taking the Pulse® study of over 2,000 U.S. physicians.
EU-funded study investigates kidney regeneration potential
- Details
- Category: Research
A paper published in The Lancet journal, as part of a series on renal medicine, has questioned if kidney regeneration may be possible in human beings as it is in fish and other lower vertebrates.
Orphan Drugs to Create Paradigm Shift in the Pharmaceutical Industry
- Details
- Category: Research
The economic recovery process has proved difficult for the pharmaceutical industry. Factors like patent expiry, dry pipeline, and strict approval guidelines, have slowed down the attractive drug discovery and industry growth. Coupled with an investment risk in new therapy or molecules, this creates a challenge for the industry to overcome.
Two Compounds Discovered that Pave the Way for New Class of AIDS Drug
- Details
- Category: Research
According to the World Health Organization, about 33 million people currently live with HIV infections. Several drugs used to treat AIDS inhibit this HIV protease target, but drug-resistant mutants that impede the effectiveness of these drugs keep appearing and getting worse.
More Pharma News ...
- Electronic Clinical Decision Support for Middle Eastern Hospitals
- Google Announces Public Data Explorer
- MitoTarget Launches New Online Resource for Physicians and Sufferers from Rare Illness ALS
- EU-funded researchers sequence human gut microbe genome
- Physicians Will Expand Range of Mobile Activities to Include Administrative and Patient Care Tasks
- Funds Boost Research into Causes, Interventions for Age-Related Cognitive Decline
- Powerful Universal Search Engine Makes Scientific Research Easy to Find